Highest-materiality recent filing
Intuitive Surgical Q2 revenue $2.89B (+19% YoY); GAAP EPS $2.29, non-GAAP $2.80
Worldwide procedures grew ~16% (da Vinci +15%, Ion +36%); 468 da Vinci systems placed (246 da Vinci 5).
Intuitive Surgical boosts buyback to $5.0B; shareholders approve plan amendment
Board increased stock repurchase authorization to $5.0B aggregate, including prior remaining balance.
Intuitive Q1 rev $2.77B (+23%), EPS $2.50 non-GAAP; procedures +17%, da Vinci placements 431
Revenue $2.77B (+23% YoY); GAAP EPS $2.28, non-GAAP EPS $2.50 (vs. $1.92/$1.81 prior year).
Intuitive Surgical completes acquisition of European distributors, expands direct ops in 5 countries
Acquisition closed March 1, 2026, of da Vinci and Ion distribution business from ab medica, Abex, Excelencia Robótica.
Q4 revenue $2.87B (+19% YoY); GAAP net income $795M ($2.21 diluted EPS); non-GAAP net income $914M ($2.53 diluted EPS).
Intuitive Surgical Q4 2025 revenue $2.87B, up 19% YoY; procedures grow 18%
Revenue $2.87B in Q4 (+19% YoY); full year $10.06B (+21%).
Intuitive Surgical Q3 revenue $2.51B (+23% YoY); EPS $1.95 GAAP / $2.40 non-GAAP; procedures +20%
Worldwide procedures grew ~20% YoY; da Vinci +19%, Ion +52%.
Intuitive Surgical Q2 revenue up 21% to $2.44B; non-GAAP EPS $2.19 vs $1.78
Revenue $2.44B (+21% YoY); GAAP diluted EPS $1.81; non-GAAP diluted EPS $2.19 (vs $1.46/$1.78 last year).
Intuitive Surgical promotes President Dave Rosa to CEO effective July 1, 2025
David J. Rosa promoted to CEO effective July 1, 2025; he previously served as President.
Board increased stock repurchase authorization to $4.0B aggregate, including prior remaining amounts.
Intuitive Q1 revenue $2.25B, EPS $1.92; procedure volume +17%
Revenue $2.25B (+19% YoY); GAAP EPS $1.92, non-GAAP EPS $1.81.
Intuitive Q4 beats: rev $2.41B, adj EPS $2.21; buys Euro distributors for ~€321M
Q4 da Vinci procedures grew ~18% YoY; 493 systems placed including 174 da Vinci 5.
Intuitive Q4 rev $2.41B (+25% YoY), procedures +18%; guides 2025 procedure growth 13-16%
Q4 preliminary revenue $2.41B, up 25% YoY; full-year 2024 revenue $8.35B, up 17%.
Intuitive Surgical Q3 revenue $2.04B (+17% YoY); GAAP EPS $1.56, non-GAAP $1.84
da Vinci procedures grew 18% YoY; placed 379 systems including 110 da Vinci 5 units.
Intuitive Surgical Q2 revenue $2.01B (+14% YoY), GAAP EPS $1.46, non-GAAP $1.78
Revenue $2.01B (+14% YoY); GAAP net income $527M ($1.46 EPS), non-GAAP $641M ($1.78 EPS).
Intuitive Q1 revenue $1.89B (+11% YoY), GAAP EPS $1.51, da Vinci procedures +16%
Q1 revenue $1.89B (+11% YoY); GAAP EPS $1.51, non-GAAP EPS $1.50; procedure volume +16%.
Intuitive announces FDA clearance of fifth-gen da Vinci 5 robotic system
FDA 510(k) clearance obtained for da Vinci 5, Intuitive's next-generation multiport surgical robot.
Intuitive Surgical Q4 2023 revenue $1.93B (+17% YoY), GAAP EPS $1.69, procedures up 21%
Revenue $1.93B (+17% vs $1.66B Q4 2022); GAAP net income $606M ($1.69/diluted share).
Intuitive Surgical Q4 revenue $1.93B (+17% YoY); 2024 procedure growth guidance 13-16%
Q4 2023 revenue $1.93B (+17% YoY); full-year 2023 revenue $7.12B (+14% YoY).
Intuitive Surgical Q3 revenue $1.74B (+12%), GAAP EPS $1.16, non-GAAP $1.46; procedures +19%
Revenue $1.74B, up 12% YoY; GAAP net income $416M ($1.16/diluted), up from $324M ($0.90) in Q3'22.
Intuitive Surgical Q2 revenue $1.76B (+15% YoY), EPS $1.18, procedures +22%
Revenue $1.76B (+15% YoY); GAAP EPS $1.18 vs $0.85; non-GAAP EPS $1.42 vs $1.14.
Intuitive Surgical Q1 revenue $1.70B (+14% YoY), da Vinci procedures +26%, non-GAAP EPS $1.23
Revenue $1.70B, up 14% YoY; constant currency growth of 17%.
Intuitive Q4 revenue $1.66B (+7%), GAAP EPS $0.91, non-GAAP $1.23; 18% procedure growth, $1B buyback
Revenue $1.66B (+7% YoY); GAAP net income $325M ($0.91/sh) vs $381M ($1.04/sh) in Q4 2021.
Intuitive Q4 revenue $1.66B (+7% YoY); procedures +18%; 2023 guidance 12-16% growth
Q4 2022 revenue $1.66B (up 7% YoY); FY22 revenue $6.22B (up 9% YoY).
Intuitive Q3 revenue $1.56B up 11% YoY; GAAP EPS $0.90 vs $1.04
Worldwide da Vinci procedures grew ~20% YoY; installed base 7,364 systems (+13%).
Intuitive Surgical enters $1B accelerated share repurchase with Goldman Sachs
Entered ASR agreement with Goldman Sachs to repurchase $1 billion of common stock.
Q2 GAAP net income $308M ($0.85 EPS) down 40% YoY; revenue $1.52B up 4%
Worldwide da Vinci procedures grew ~14% YoY; system placements 279 (down 15%).
Intuitive Surgical Q1 revenue $1.49B (+15%), GAAP EPS $1.00 vs $1.17 YoY
da Vinci procedures grew ~19% YoY; compound annual growth from Q1 2019 was ~15%.
Intuitive Q4 revenue $1.55B (+17% YoY); da Vinci procedures +19%; GAAP EPS $1.04, non-GAAP $1.30
GAAP net income $381M ($1.04/diluted share); non-GAAP net income $477M ($1.30/diluted share).
Intuitive Surgical Q4 revenue $1.55B (+17%), FY2021 $5.71B (+31%), da Vinci procedures +19% in Q4
Q4 2021 revenue $1.55B (+17% YoY); FY2021 revenue $5.71B (+31% YoY).
Intuitive Surgical Q3 rev $1.40B (+30% YoY), EPS $1.04; names Jamie Samath CFO
Q3 revenue $1.40B (+30% YoY); GAAP net income $381M ($1.04 diluted EPS); non-GAAP $435M ($1.19 diluted EPS).
Intuitive Surgical announces 3-for-1 stock split, pending shareholder vote on Sept. 20
Board approved a 3-for-1 split via amendment to certificate of incorporation; authorized shares to increase from 300M to 600M.
Revenue $1.46B (+72% YoY); procedure growth 68% YoY; compound annual growth 16.5% from Q2 2019.
Taylor Patton, Global Senior Vice President, Endoluminal will succeed Mr. Charlton as the Company’s Chief Commercial and Marketing Officer.
Effective July 1, 2026, Henry L. Charlton will transition from his role as Chief Commercial and Marketing Officer of Intuitive Surgical, Inc. (the “Company”) and begin serving as Senior Vice President of Global Business Operations of the Company.
On May 14, 2025, the Board of Directors (the “Board”) of Intuitive Surgical, Inc. (the “Company”) appointed David J. Rosa, currently the Company’s President, as Chief Executive Officer of the Company effective July 1, 2025.
the independent directors of the Board appointed Craig H. Barratt, Ph.D., the Board’s current Chair, to serve as the lead independent director of the Board also effective July 1, 2025.
Mr. Rosa will replace Gary S. Guthart, Ph.D., who will step down as Chief Executive Officer of the Company effective July 1, 2025 and will assume the position of Executive Chair of the Board as of that same date, and will continue to serve as a director.
Effective January 1, 2025, Jamie E. Samath was promoted to serve as Executive Vice President, Chief Financial Officer and Head of Business Technology of Intuitive Surgical, Inc. (the “Company”).
In addition, effective January 1, 2025, Henry L. Charlton was promoted to serve as Executive Vice President, Chief Commercial and Marketing Officer of the Company.
On July 24, 2024, the Board of Directors (the “Board”) of Intuitive Surgical, Inc. (the “Company”) appointed David J. Rosa to the Board effective as of July 24, 2024.
On April 25, 2024, the Board of Directors (the “Board”) appointed Lewis Chew to succeed Mark J. Rubash as Chair of the Audit Committee.
Alan J. Levy, Ph.D., who did not stand for re-election at the Annual Meeting
appointed Sreelakshmi Kolli to the Board effective as of October 27, 2023.
On May 15, 2023, the Board of Directors of Intuitive Surgical, Inc. (the “Company” or “Intuitive”) promoted David J. Rosa to the role of President of the Company, effective May 16, 2023.
Max materiality 0.85 · Median 0.75 · Most common event earnings